uPAR-targeting moieties, such as the AE105 peptide and ATF, have been successfully employed by several groups to engineer and guide drug-loaded nanoparticles (NPs) selectively to tumor sites (Table 4). The gene discussed is PLAUR; the disease is neoplasm.